Measurement of serum Anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA:: Comparison and relevance in Assisted Reproduction Technology (ART)

被引:101
作者
Freour, Thomas
Mirallie, Sophie
Bach-Ngohou, Kalyane
Denis, Marc
Barriere, Paul
Masson, Damien
机构
[1] CHU Nantes, Inst Biol, Lab Biochim Specialisee, Dept Human Reprod, F-44035 Nantes, France
[2] CHU Nantes, Clin Chem Lab, F-44035 Nantes, France
关键词
anti-Mullerian hormone; ELISA; method comparison; ovarian reserve; pregnancy;
D O I
10.1016/j.cca.2006.06.013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Numerous studies have evocated the clinical usefulness of serum AMH levels as a predictor of ovarian response and pregnancy in assisted reproductive technology cycles. Nevertheless, the analysis of the literature shows a great dispersion in serum AMH concentrations obtained with different methods from almost comparable populations. Methods: We compared two commercial immunoassays (AMH Beckman Coulter ELISA and AMH DSL ELISA) and we evaluated the AMH levels in serum as a prognosis value for ovarian response and pregnancy in assisted reproductive technology cycles. Results: We found a close linear relationship between the two methods but AMH levels were almost 4.6-fold lower with the DSL kit than with the Beckman Coulter kit. We found a significant and positive correlation between the number of mature ovocytes inseminated and AMH levels obtained with the two methods. Whatever the ELISA used, we found no significant difference between AMH level of pregnancy and non pregnancy groups. Indeed, using the Beckman Coulter method, all pregnant patients had serum AMH levels over 1.4 mu g/L. Conversely, no cut-off value can be found for the DSL kit. Conclusion: Our results show clearly for the first time that AMH results are method dependent even if the correlation obtained between the two methods remained excellent. The Beckman Coulter AMH ELISA should produce clinical agreement when used for prognosis purposes on patients undergoing assisted reproduction. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:162 / 164
页数:3
相关论文
共 10 条
[1]   Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 [J].
Fanchin, R ;
Schonäuer, LM ;
Righini, C ;
Guibourdenche, J ;
Frydman, R ;
Taieb, J .
HUMAN REPRODUCTION, 2003, 18 (02) :323-327
[2]   Early follicular antimullerian hormone as an indicator OT ovarian reserve [J].
Fiçicioglu, C ;
Kutlu, T ;
Baglam, E ;
Bakacak, Z .
FERTILITY AND STERILITY, 2006, 85 (03) :592-596
[3]   Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol [J].
Hazout, A ;
Bouchard, P ;
Seifer, DB ;
Aussage, P ;
Junca, AM ;
Cohen-Bacrie, P .
FERTILITY AND STERILITY, 2004, 82 (05) :1323-1329
[4]   Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? [J].
Muttukrishna, S ;
Suharjono, H ;
McGarrigle, H ;
Sathanandan, M .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2004, 111 (11) :1248-1253
[5]   Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization [J].
Nakhuda, Gary S. ;
Chu, Micheline C. ;
Wang, Jeff G. ;
Sauer, Mark V. ;
Lobo, Rogerio A. .
FERTILITY AND STERILITY, 2006, 85 (05) :1541-1543
[6]   Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment [J].
Peñarrubia, J ;
Fábregues, F ;
Manau, D ;
Creus, M ;
Casals, G ;
Casamitjana, R ;
Carmona, F ;
Vanrell, JA ;
Balasch, J .
HUMAN REPRODUCTION, 2005, 20 (04) :915-922
[7]   AMH/MIS:: what we know already about the gene, the protein and its regulation [J].
Rey, R ;
Lukas-Croisier, C ;
Lasala, C ;
Bedecarrás, P .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2003, 211 (1-2) :21-31
[8]   Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles [J].
Seifer, DB ;
MacLaughlin, DT ;
Christian, BP ;
Feng, B ;
Shelden, RM .
FERTILITY AND STERILITY, 2002, 77 (03) :468-471
[9]   Mullerian inhibiting substance: An instructive developmental hormone with diagnostic and possible therapeutic applications [J].
Teixeira, J ;
Maheswaran, S ;
Donahoe, PK .
ENDOCRINE REVIEWS, 2001, 22 (05) :657-674
[10]   Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve [J].
van Rooij, IAJ ;
Broekmans, FJM ;
te Velde, ER ;
Fauser, BCJM ;
Bancsi, LFJMM ;
de Jong, FH ;
Themmen, APN .
HUMAN REPRODUCTION, 2002, 17 (12) :3065-3071